Immunoprecipitation of EGFR from EGF-treated A431 cells by monoclonal antibodies MA1-10330 (A), MA1-10329 (B), a commercial anti-EGFR polyclonal antibody (C) and anti-EGFR monoclonal mAb108 (D). The precipitates were immunoblotted with MA1-10330 or MA1-10329 antibody, and goat anti-mouse-HRP.
|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Synthetic phospho-peptide covering sequence around tyrosine 992 of human EGFR.|
|Storage buffer||PBS, pH 7.4|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||2-8 ug/ml|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||1 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The oncoprotein EGFR (epidermal growth factor receptor), also known as HER1 / ErbB1, is a member of ErbB family of cell surface receptor tyrosine kinases. This 170 kDa transmembrane glycoprotein is often associated with cancerogenesis, although its activation state is controlled at various levels including trafficking and degradation steps. Binding of receptor-specific ligands to the EGFR ectodomain results in formation of homodimeric or heterodimeric kinase-active complexes into which HER2 / ErbB2 is recruited as a preferred partner. Subsequent signaling cascades such as RAS/MAPK and PI3K/AKT pathways lead to cell proliferation and survival responses.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.